使用长效钴胺素制剂倍托维克斯对恶性贫血进行长期治疗。

Long term therapy of pernicious anaemia with the depot cobalamin preparation betolvex.

作者信息

Bastrup-Madsen P, Helleberg-Rasmussen I, Nørregaard S, Halver B, Hansen T

出版信息

Scand J Haematol. 1983 Jul;31(1):57-62. doi: 10.1111/j.1600-0609.1983.tb02137.x.

DOI:10.1111/j.1600-0609.1983.tb02137.x

Abstract

The value of a depot cobalamin preparation Betolvex (cyanocobalamin-tannin complex suspended in a sesame-oil aluminum-monostearate gel) in the maintenance therapy of pernicious anaemia was investigated in 120 patients followed up for between 8 and 15 years. Complete haematological remission was maintained in all patients, and none developed B12 neuropathy after the start of treatment. No side-effects were observed. The mean values of S-cobalamin were above the reference limits when 1 mg cobalamin was given every 2 months, and high within the reference limits when given at 3 monthly intervals. The cobalamin content in the liver tissue in 2 patients who had received 1 mg cobalamin every 3 months for 6 years revealed normal values. Thus, 1 mg of the depot cobalamin preparation given at intervals of 3 months should provide adequate maintenance therapy in pernicious anaemia.

摘要

对120例随访8至15年的患者，研究了长效钴胺素制剂Betolvex（氰钴胺-单宁复合物悬浮于芝麻油单硬脂酸铝凝胶中）在恶性贫血维持治疗中的价值。所有患者均维持完全血液学缓解，治疗开始后无一例发生B12神经病变。未观察到副作用。每2个月给予1 mg钴胺素时，血清钴胺素平均值高于参考范围，每3个月给药时则在参考范围内偏高。2例接受每3个月1 mg钴胺素治疗6年的患者，其肝组织中的钴胺素含量显示正常。因此，每3个月给予1 mg长效钴胺素制剂应能为恶性贫血提供足够的维持治疗。